The Role of Pan-Immune-Inflammation Value in Predicting Contrast-Induced Nephropathy Development in Patients Undergoing Percutaneous Coronary Intervention Due to NSTEMI.

contrast-induced nephropathy non-ST segment elevation myocardial infarction pan-immune-inflammation value percutaneous coronary intervention

Journal

Angiology
ISSN: 1940-1574
Titre abrégé: Angiology
Pays: United States
ID NLM: 0203706

Informations de publication

Date de publication:
30 Oct 2023
Historique:
medline: 31 10 2023
pubmed: 31 10 2023
entrez: 30 10 2023
Statut: aheadofprint

Résumé

Contrast-induced nephropathy (CIN), which can develop after procedures involving contrast agents, is a significant cause of patient morbidity and mortality. This study aims to investigate the role of pre-procedural pan-immune-inflammation value (PIV) in predicting CIN development in patients undergoing percutaneous coronary intervention (PCI) due to non-ST segment elevation myocardial infarction (NSTEMI). A total of 1006 NSTEMI patients were included in the study. CIN was defined as an increase of at least 0.5 mg/dl or 25% in serum baseline creatinine level 72 h after the procedure. Patients were divided into two groups: those with and without CIN. NSTEMI patients who developed CIN, glucose level (

Identifiants

pubmed: 37903550
doi: 10.1177/00033197231211107
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

33197231211107

Déclaration de conflit d'intérêts

Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Auteurs

Zeki Cetinkaya (Z)

Department of Cardiology, Elazıg Fethi Sekin City Hospital, Elazıg, Turkey.

Saban Kelesoglu (S)

Department of Cardiology, Erciyes University Faculty of Medicine, Melikgazi, Turkey.

Classifications MeSH